Slate Path Capital’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Slate Path Capital’s Portfolio NEXI Stock Details NEXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-36,999	Closed	-$102K	–	75
2024 Q2	$102K	Hold	36,999	–	–	﹤0.01%	59
2024 Q1	$208K	Hold	36,999	–	–	﹤0.01%	59
2023 Q4	$82.1K	Sell	36,999 -1	-0%	-$3	﹤0.01%	57
2023 Q3	$194K	Hold	37,000	–	–	0.01%	45
2023 Q2	$261K	Hold	37,000	–	–	0.01%	44
2023 Q1	$352K	Buy	+37,000	New	+$389K	0.02%	38
2022 Q4	–	Sell	-37,000	Closed	-$513K	–	51
2022 Q3	$513K	Hold	37,000	–	–	0.03%	43
2022 Q2	$1.49M	Hold	37,000	–	–	0.09%	38
2022 Q1	$3.89M	Hold	37,000	–	–	0.2%	34
2021 Q4	$4.26M	Hold	37,000	–	–	0.22%	32
2021 Q3	$14M	Hold	37,000	–	–	0.64%	27
2021 Q2	$15.1M	Hold	37,000	–	–	0.84%	23
2021 Q1	$17.6M	Buy	+37,000	New	+$20.1M	1.14%	18

Other funds holding NEXI

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Slate Path Capital's NEXI Position: Q3 2024 in Review

Slate Path Capital sold out of NexImmune, Inc. Common Stock (NEXI) in Q3 2024, closing a stake of 36,999 shares — an estimated $102K sold.

Slate Path Capital first reported a position in NEXI in Q1 2021 and held it in 13 quarters. The position peaked at $17.6M in Q1 2021. 1 fund tracked by Wall St. Rank holds NEXI as of Q3 2024.

Slate Path Capital reported no remaining NexImmune, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Slate Path Capital sold 36,999 NexImmune, Inc. Common Stock shares in Q3 2024, an estimated $102K.
Slate Path Capital first reported a position in NexImmune, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
Slate Path Capital's NexImmune, Inc. Common Stock position peaked at $17.6M in Q1 2021.
1 fund tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q3 2024.

Based on Slate Path Capital's 13F filing for Q3 2024, filed 14 Nov 2024.